JP2022502421A5 - - Google Patents

Info

Publication number
JP2022502421A5
JP2022502421A5 JP2021517030A JP2021517030A JP2022502421A5 JP 2022502421 A5 JP2022502421 A5 JP 2022502421A5 JP 2021517030 A JP2021517030 A JP 2021517030A JP 2021517030 A JP2021517030 A JP 2021517030A JP 2022502421 A5 JP2022502421 A5 JP 2022502421A5
Authority
JP
Japan
Application number
JP2021517030A
Other languages
Japanese (ja)
Other versions
JP7500550B2 (ja
JP2022502421A (ja
JPWO2020074697A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/077578 external-priority patent/WO2020074697A1/en
Publication of JP2022502421A publication Critical patent/JP2022502421A/ja
Publication of JP2022502421A5 publication Critical patent/JP2022502421A5/ja
Publication of JPWO2020074697A5 publication Critical patent/JPWO2020074697A5/ja
Priority to JP2024091857A priority Critical patent/JP2024116245A/ja
Application granted granted Critical
Publication of JP7500550B2 publication Critical patent/JP7500550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517030A 2018-10-12 2019-10-11 乾性眼疾患の治療のための眼科用組成物 Active JP7500550B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091857A JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18200154 2018-10-12
EP18200154.5 2018-10-12
EP18202263 2018-10-24
EP18202263.2 2018-10-24
EP19167551.1 2019-04-05
EP19167551 2019-04-05
PCT/EP2019/077578 WO2020074697A1 (en) 2018-10-12 2019-10-11 Ophthalmic composition for treatment of dry eye disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091857A Division JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Publications (4)

Publication Number Publication Date
JP2022502421A JP2022502421A (ja) 2022-01-11
JP2022502421A5 true JP2022502421A5 (https=) 2023-08-16
JPWO2020074697A5 JPWO2020074697A5 (https=) 2023-08-16
JP7500550B2 JP7500550B2 (ja) 2024-06-17

Family

ID=68138117

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517030A Active JP7500550B2 (ja) 2018-10-12 2019-10-11 乾性眼疾患の治療のための眼科用組成物
JP2024091857A Pending JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091857A Pending JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Country Status (12)

Country Link
US (3) US11413323B2 (https=)
EP (2) EP3863658B1 (https=)
JP (2) JP7500550B2 (https=)
CN (1) CN112823020A (https=)
AU (1) AU2019358249B2 (https=)
CA (1) CA3112031A1 (https=)
ES (1) ES2974839T3 (https=)
IL (1) IL281773B2 (https=)
MY (1) MY206642A (https=)
PH (1) PH12021550620A1 (https=)
SG (1) SG11202102820VA (https=)
WO (1) WO2020074697A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) * 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
JP7749020B2 (ja) 2021-02-03 2025-10-03 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物
WO2024133913A2 (en) * 2022-12-23 2024-06-27 Novaliq Gmbh Semifluorinated alkane compositions comprising hyoscyamine
CN120916776A (zh) * 2023-02-13 2025-11-07 诺瓦利克有限责任公司 用于眼表疾病患者的眼部手术准备的眼用组合物
WO2026022741A1 (en) * 2024-07-23 2026-01-29 Alcon Inc. Acoltremon combinations with lifitegrast or cyclosporin and uses thereof

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JPH03279323A (ja) 1989-12-15 1991-12-10 Johnson & Johnson Consumer Prod Inc 日焼け止め組成物
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5849291A (en) 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
ATE266397T1 (de) 1997-02-04 2004-05-15 Murray A Johnstone Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
DE60223694T2 (de) 2001-09-04 2008-10-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP3998596B2 (ja) 2003-03-31 2007-10-31 日本ペイント株式会社 塗膜ムラの算出式算出方法及び塗膜ムラの数値化方法
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
JP2007511616A (ja) 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
KR20080043793A (ko) 2005-08-05 2008-05-19 바라트 쎄럼스 앤드 백신스 리미티드 방부 효능을 갖는 정맥 프로포폴 에멀젼 조성물
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
WO2008070490A2 (en) 2006-11-28 2008-06-12 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
WO2010062394A2 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
JP5670200B2 (ja) 2008-12-02 2015-02-18 ロート製薬株式会社 眼科用組成物
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
CA2756528A1 (en) 2009-04-17 2010-10-21 Celavista Pharmaceuticals Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
CN102802619A (zh) 2009-06-25 2012-11-28 狮王株式会社 眼科用组合物
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
SI2387391T1 (sl) 2009-07-24 2017-04-26 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Postopek za pripravo tekočega sestavka, ki se nanaša na kožo v obliki pene, in sestavka, ki se lahko nanaša topično
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2661280T3 (en) 2011-01-04 2019-03-04 Novaliq Gmbh O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
PL2968650T3 (pl) 2013-03-14 2019-05-31 Panoptica Inc Preparaty do oczu do dostarczania leku do tylnego fragmentu oka
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MX376125B (es) 2014-03-31 2025-03-07 Amcor Rigid Plastics Usa Llc Recipiente de liberacion controlada.
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
JP6660939B2 (ja) 2014-08-13 2020-03-11 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 点眼剤からの保存剤除去
EA034839B1 (ru) 2014-10-20 2020-03-26 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
EP3362096B1 (en) 2015-10-14 2023-12-13 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
WO2017135918A1 (en) 2016-02-04 2017-08-10 Dyer Gordon Wayne Method for impairing a cassie-baxter state
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
EP3558308A1 (en) 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
JP2022502421A5 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021017732A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)